REGENXBIO Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
REGENXBIO Inc. (RGNX) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$5.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-06
- REGENXBIO Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was -$5.00K, a 141.67% decline year-over-year.
- REGENXBIO Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-06-30 was $12.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month |
|---|---|---|
| 2026-06-30 | -$5.00K 10-Q · filed 2026-08-06 | -$188.00K 10-Q · filed 2026-08-06 |
| 2025-06-30 | $12.00K 10-Q · filed 2026-08-06 | -$9.00K 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |